Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Winning Combination loses NAD challenge

This article was originally published in The Tan Sheet

Executive Summary

The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette, Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1"The Tan Sheet" Aug. 6, 2007, In Brief)

The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette , Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1 'The Tan Sheet' Aug. 6, 2007, In Brief).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel